Key statistics
As of last trade Disc Medicine Inc (IRON:NMQ) traded at 65.12, -16.08% below its 52-week high of 77.60, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 63.34 |
---|---|
High | 65.46 |
Low | 62.61 |
Bid | 65.07 |
Offer | 65.29 |
Previous close | 63.51 |
Average volume | 296.95k |
---|---|
Shares outstanding | 29.73m |
Free float | 25.33m |
P/E (TTM) | -- |
Market cap | 1.89bn USD |
EPS (TTM) | -3.97 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 19:24 GMT.
More ▼
- Disc Medicine to Participate in Upcoming Investor Conferences
- Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
- Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
- Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
- Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
- Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
- Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
- Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
- Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
More ▼